论文部分内容阅读
北京是首善之都,北京的药店承担着为两千多万北京人口护佑健康的重任,但谁能想得到北京药品零售市场的发展如此步履维艰,其连锁药店更是左右为难,前途堪忧。须知药品零售业的大背景,是京外的连锁药店正在抓住处方药网售放开、政策与环境逐步转暖、行业集中度正在提高等有利因素加快发展做大做强;偏隅云南的鸿翔一心堂则于7月2日IPO上市成为真正的“药店第一股”。北京连锁药店的发展,是当前我国连锁药店发展的真实写照。原因是多方面的。首先是政策不
Beijing is the capital of the nation’s best. Beijing’s drug stores bear the responsibility of protecting the health of more than 20 million Beijing residents. However, anyone who can imagine the development of Beijing’s drug retail market is so struggling that its chain pharmacies are daunting and have a terrible future. Given the background of the pharmaceutical retail industry, chain pharmacies outside Beijing are seizing the advantages of open online pharmacy sales of prescription drugs, the gradual warming of policies and the environment, the increasing concentration of industries, and other favorable factors to speed up development. The development of Yunnan Hong Xiang Yixintang was listed on the IPO on July 2 to become the real “pharmacy first unit.” The development of chain pharmacies in Beijing is a true reflection of the current development of China’s chain pharmacies. There are many reasons. The first is the policy is not